- Home
- ROOT vs MESO Comparison
ROOT vs MESO Comparison
Compare ROOT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROOT
- MESO
- Stock Information
- Founded
- ROOT 2015
- MESO 2004
- Country
- ROOT United States
- MESO Australia
- Employees
- ROOT N/A
- MESO N/A
- Industry
- ROOT Property-Casualty Insurers
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ROOT Finance
- MESO Health Care
- Exchange
- ROOT Nasdaq
- MESO Nasdaq
- Market Cap
- ROOT 2.1B
- MESO 1.7B
- IPO Year
- ROOT 2020
- MESO N/A
- Fundamental
- Price
- ROOT $136.93
- MESO $12.11
- Analyst Decision
- ROOT Buy
- MESO Buy
- Analyst Count
- ROOT 7
- MESO 4
- Target Price
- ROOT $87.00
- MESO $18.00
- AVG Volume (30 Days)
- ROOT 835.8K
- MESO 347.4K
- Earning Date
- ROOT 04-29-2025
- MESO 02-26-2025
- Dividend Yield
- ROOT N/A
- MESO N/A
- EPS Growth
- ROOT N/A
- MESO N/A
- EPS
- ROOT 1.83
- MESO N/A
- Revenue
- ROOT $1,176,500,000.00
- MESO $5,670,000.00
- Revenue This Year
- ROOT $9.56
- MESO $228.57
- Revenue Next Year
- ROOT $12.72
- MESO $356.77
- P/E Ratio
- ROOT $74.83
- MESO N/A
- Revenue Growth
- ROOT 158.57
- MESO N/A
- 52 Week Low
- ROOT $34.04
- MESO $4.60
- 52 Week High
- ROOT $181.14
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- ROOT 48.80
- MESO 30.53
- Support Level
- ROOT $147.01
- MESO $13.60
- Resistance Level
- ROOT $181.14
- MESO $14.45
- Average True Range (ATR)
- ROOT 13.24
- MESO 0.52
- MACD
- ROOT -1.93
- MESO 0.05
- Stochastic Oscillator
- ROOT 16.35
- MESO 5.65
About ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. The company is a direct-to-consumer personal auto insurance, renters insurance and mobile technology company. It generates revenue from the sale of auto insurance policies within the United States.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.